Plasma Kallikrein Inhibitor

This page covers all Plasma Kallikrein Inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Plasma kallikrein, Plasma kallikrein (Factor XIa), Plasma kallikrein (Factor XIa substrate).

Targets

Plasma kallikrein · Plasma kallikrein (Factor XIa) · Plasma kallikrein (Factor XIa substrate)

Marketed (1)

• Orladeyo · Biocryst · Neuroscience
  Orladeyo works by blocking the plasma kallikrein enzyme, which is involved in the production of bradykinin, a key mediator of HAE symptoms.

Phase 3 pipeline (1)

• BCX7353 capsules · BioCryst Pharmaceuticals · Immunology / Rare Disease
  BCX7353 is a selective inhibitor of plasma kallikrein that reduces bradykinin generation in the contact system pathway.

Phase 2 pipeline (1)

• BCX7353 · BioCryst Pharmaceuticals · Immunology / Rare Disease
  BCX7353 is a selective inhibitor of plasma kallikrein that reduces bradykinin generation in the contact system pathway.